

## RNAI TECHNOLOGIES AND GLOBAL MARKETS



**BIO127B**  
**January 2016**

Shalini Shahani Dewan  
***Project Analyst***

ISBN: 1-62296-221-4



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
RIBONUCLEIC ACID (RNA)	10
EVOLUTION OF RNA	10
<i>TABLE 1 EVOLUTION OF RNA</i>	11
RNA INTERFERENCE (RNAI)	12
MECHANISM OF ACTION OF RNA INTERFERENCE	12
MicroRNA (miRNA)	13
<i>TABLE 2 MICRORNA (MIRNA) DATABASES</i>	14
Short Interfering RNA (siRNA)	14
<i>TABLE 3 SHORT/SMALL INTERFERING RNA (SIRNA) DATABASES</i>	15
Small Hairpin RNA (shRNA)	16
Piwi-Interacting RNA (piRNA)	16
<i>TABLE 4 PIWI-INTERACTING RNA (PIRNA) DATABASES</i>	17
RNA INTERFERENCE DRUG DELIVERY	17
SYSTEMIC ELIMINATION OF SIRNA	18
SIRNA STABILITY IN BLOODSTREAM	18
RETICULOENDOTHELIAL SYSTEM (RES) ENTRAPMENT	19
VASCULAR ENDOTHELIUM	19
DIFFUSION	19
PLASMA MEMBRANE	19
ENDOSOMAL ENTRAPMENT	19
NANO-CARRIER MEDIATED TOXICITY	20
METHODS OF RNA INTERFERENCE DRUG DELIVERY SYSTEMS	20
Physical RNAi Delivery Methods	20
Hydrodynamic Injection	20
Electroporation	21
Vector-Based RNAi Delivery Methods	21
Plasmid Vector RNAi Delivery	21

<b>TOPIC</b>	<b>PAGE NO.</b>
Virus Vector RNAi Delivery	21
Carrier-Based Nonviral RNAi Delivery	22
Cationic Cell-Penetrating Peptide (CPP)	22
Aptamer	23
Lipid-Based siRNA Delivery	23
<i>TABLE 5 STABILIZATION METHODS FOR LIPID BASED SIRNA DELIVERY SYSTEM</i>	24
Polymer- and Peptide-Based Vector	25
Lipid-Polymer Combination	26
Dendrimers	26
Phi29 Packaging RNA	26
Mesoporous Silica Nanoparticles	27
Antibodies	27
Stem Cell	27
Light-Controlled Delivery	28
Quaternized Starch Based Carrier	28
<b>RNAI DRUG DISCOVERY AND DEVELOPMENT</b>	28
<b>RNA-BASED THERAPIES</b>	28
Antisense RNA Therapy	29
Ribosome RNA Therapy	29
Aptamer RNA Therapy	30
Messenger RNA (mRNA) Therapeutics	31
RNAi Therapeutics	31
Drug Discovery	32
Targeting miRNA Processes	32
Delivering Designed siRNAs Into Cells	32
Drug Target Validation	32
Designing RNAi Therapeutics	33
Sequence Selection	33
Chemical and Structure Modification	33
Drug Development	34
RNAi Instability	34
Off-Target Effects	34
Innate/Intrinsic Immune Response	35
Delivery Material Toxicity	35
Saturation of RNAi Machinery	36
<b>OTHER POTENTIAL APPLICATIONS OF RNA INTERFERENCE</b>	36
<b>DIAGNOSTICS</b>	36
<b>AGRICULTURE</b>	36
<b>CHAPTER 4 NEW DEVELOPMENTS AND REGULATORY ACTIVITY</b>	39
<b>NEW DEVELOPMENTS</b>	39
<i>TABLE 6 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF RNAI THERAPEUTICS AND TECHNOLOGIES AS OF SEPTEMBER 2015</i>	40
<b>REGULATORY ASPECTS</b>	43
<b>REGULATORY DEVELOPMENTS</b>	43
<b>COLLABORATIVE TRIALS AND FUTURE ACTIVITIES</b>	44
<b>CHAPTER 5 MARKET ANALYSIS</b>	48

<b>TOPIC</b>	<b>PAGE NO.</b>
MARKET BY TECHNOLOGY	49
<i>TABLE 7 GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	50
<i>FIGURE 1 GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, 2013-2020 (\$ MILLIONS)</i>	50
MARKET SHARE	50
<i>TABLE 8 MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)</i>	51
<i>FIGURE 2 MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)</i>	51
RNA INTERFERENCE RESEARCH TOOLS AND REAGENTS	51
RNAi Research Tools and Constructs	52
<i>TABLE 9 MODIFICATIONS OF SIRNA</i>	52
<i>TABLE 10 RNAI VECTORS</i>	53
Reagents	54
Market Overview	54
Market Revenue	56
<i>TABLE 11 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, THROUGH 2020 (\$ MILLIONS)</i>	56
<i>FIGURE 3 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, 2013-2020 (\$ MILLIONS)</i>	56
Market Share	57
<i>TABLE 12 MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)</i>	57
<i>FIGURE 4 MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)</i>	57
RNAI INTERFERENCE THERAPEUTICS	58
<i>TABLE 13 DISEASE-SPECIFIC TARGET GENES/PROTEINS FOR RNAI THERAPEUTICS</i>	59
GLOBAL PHARMACEUTICAL MARKET	60
<i>TABLE 14 GLOBAL PHARMACEUTICAL MARKET, THROUGH 2020 (\$ BILLIONS)</i>	60
<i>FIGURE 5 GLOBAL PHARMACEUTICAL SALES MARKET, 2013-2020 (\$ BILLIONS)</i>	60
Market Share of Pharmaceutical Products by Region	61
<i>TABLE 15 GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)</i>	61
<i>FIGURE 6 GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)</i>	61
Sales of Top Pharmaceutical Companies	61
<i>TABLE 16 TOP GLOBAL PHARMACEUTICAL COMPANIES BY SALES, 2014 (\$ MILLIONS)</i>	62
Diseases	62
Cardiovascular Disease	62
Pulmonary Disease	63
Central Nervous System (CNS) Disease	63
Alzheimer's Disease (AD)	63
Parkinson's Disease (PD)	64
Huntington's Disease (HD)	64
Oncology	64
Breast Cancer	65
Pancreatic Cancer	65
Ovarian Cancer	65
Liver Cancer	66
Renal Cancer	66
Colon Cancer	67
Lung Cancer	67

<b>TOPIC</b>	<b>PAGE NO.</b>
Brain Tumor	67
Prostate Cancer	68
Age-Related Macular Degeneration (AMD)	68
Global Outlook of Therapeutic Spending for Certain Diseases	69
<i>TABLE 17 GLOBAL OUTLOOK OF THERAPEUTIC SPENDING BY DISEASE, THROUGH 2018 (\$ BILLION/%)</i>	69
Market Overview	70
RNAI DIAGNOSTICS	73
<i>TABLE 18 NUMBER OF PUBLICATIONS ASSOCIATED WITH MIRNA AND DISEASES, OCTOBER 2015</i>	73
miRNA in Cancer Diagnostics	74
<i>TABLE 19 MIRNA IN VARIOUS CANCER TYPES</i>	75
<i>TABLE 20 MIRNA AND TARGET GENE PAIRS IN VARIOUS CANCER TYPES</i>	77
miRNAs as Diagnostic, Prognostic and Predictive Biomarkers	79
<i>TABLE 21 BIOMARKERS IN VARIOUS CANCER TYPES</i>	80
Market Overview	84
Market Revenue	85
<i>TABLE 22 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, THROUGH 2020 (\$ MILLIONS)</i>	86
<i>FIGURE 7 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, 2013-2020 (\$ MILLIONS)</i>	86
Revenue for Global mRNA Research Tools Market	86
<i>TABLE 23 GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, THROUGH 2020 (\$ MILLIONS)</i>	87
<i>FIGURE 8 GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, 2013-2020 (\$ MILLIONS)</i>	87
RNA INTERFERENCE IN AGRICULTURE	87
Virus Control Through RNAi	88
Safety Concerns	89
<i>TABLE 24 SAFETY ISSUES WITH RNAI CROP IMPROVEMENT</i>	89
RNAi In Crops	91
<i>TABLE 25 PLANT IMPROVEMENT AREAS THROUGH RNAI TECHNOLOGIES</i>	92
<i>TABLE 26 REGIONS, GENES AND APPLICATION OF RNAI-TARGETING ORGANISMS FOR IMPROVEMENT OF CROPS</i>	92
RNAi In Aquaculture	93
Market Overview	94
MARKET BY REGION	95
MARKET OVERVIEW	95
MARKET REVENUE	96
RNAi Research Tools and Reagents	96
<i>TABLE 27 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	97
<i>FIGURE 9 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2013-2020 (\$ MILLIONS)</i>	97
Market Share	97
<i>TABLE 28 GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)</i>	97
<i>FIGURE 10 GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)</i>	98
RNAi Diagnostics	98

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 29 GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	99
<i>FIGURE 11 GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, 2013-2020 (\$ MILLIONS)</i>	99
Market Share	99
<i>TABLE 30 GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)</i>	100
<i>FIGURE 12 GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)</i>	100
CHAPTER 6 INDUSTRY STRUCTURE	102
RNAI RESEARCH TOOLS AND REAGENTS	102
MARKET LEADERS	102
<i>TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF RNAI RESEARCH TOOLS AND REAGENTS, 2014</i>	102
MARKET SHARES	108
<i>TABLE 32 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)</i>	108
<i>FIGURE 13 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)</i>	109
RNAI DIAGNOSTICS	109
MARKET LEADERS	109
<i>TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF RNAI DIAGNOSTICS, 2014</i>	109
MARKET SHARES	110
<i>TABLE 34 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)</i>	110
<i>FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)</i>	110
CHAPTER 7 PATENT ANALYSIS	112
PATENTS BY YEAR	113
<i>TABLE 35 TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015</i>	113
<i>FIGURE 15 TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015</i>	113
PATENTS BY COUNTRY FOR RNA INTERFERENCE TECHNOLOGIES	113
<i>TABLE 36 NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015</i>	114
<i>TABLE 37 PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)</i>	115
<i>FIGURE 16 PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)</i>	115
PATENTS BY COMPANY FOR RNA INTERFERENCE TECHNOLOGIES	116
<i>TABLE 38 NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COMPANY, 2013-AUGUST 2015</i>	117
PATENTS BY ASSIGNEE FOR RNA INTERFERENCE TECHNOLOGIES	119
<i>TABLE 39 NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST 2015</i>	120
<i>FIGURE 17 NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST, 2015</i>	120
CHAPTER 8 CURRENT STATUS	122
INNOVATIVE TECHNOLOGIES AND PLATFORMS FOR RNA INTERFERENCE	123

<b>TOPIC</b>	<b>PAGE NO.</b>
DYNAMIC POLYCONJUGATE (DPC) PLATFORM-ARROWHEAD RESEARCH CORP.)	123
CONJUGATE DELIVERY PLATFORMS - ESC-GALNAC-CONJUGATE (ALNYLAM PHARMACEUTICALS INC.)	124
LIPID NANOPARTICLE (LNP) TECHNOLOGY (ARBUTUS BIOPHARMA CORP)	124
SIRNA TECHNOLOGY PLATFORM (QUARK PHARMACEUTICALS INC.)	124
MODIFIED MESSENGER RNA THERAPEUTICS PLATFORM (MODERNA THERAPEUTICS)	124
RNAI TECHNOLOGY PLATFORMS (GE DHARMACON)	125
On-TARGETplus siRNAs	125
Reverse Transfection Format (RTF) siRNA Libraries	125
Cherry-Pick RNAi Libraries	125
Human siRNA Libraries	125
Custom siRNA Synthesis	126
Accell siRNA	126
Mouse Accell siRNA Library - Protein Kinases	126
siGENOME siRNAs	126
Lincode siRNAs	126
Lincode siRNA Libraries	127
SMARTvector Lentiviral shRNA	127
SMARTvector Inducible Lentiviral shRNA	127
SMARTvector Lentiviral shRNA Pooled Libraries	127
GIPZ Lentiviral shRNA	127
TRIPZ Inducible Lentiviral shRNA	128
The RNAi Consortium (TRC) Lentiviral shRNA Library	128
Decode Pooled Lentiviral shRNA Screening Libraries and Reagents	128
Viral Packaging Kits	128
siRNA and microRNA Transfection Reagents	129
DharmaFECT Duo Transfection Reagent	129
RNAI TECHNOLOGIES (THERMO FISHER SCIENTIFIC)	129
Silencer Select siRNA	129
Silencer Select siRNA Libraries	129
Stealth RNAi siRNAs	129
BLOCK-iT siRNAs	130
Controls for RNAi Mechanism	130
RNAI TOOLS FROM SIGMA-ALDRICH	130
MISSION siRNA	130
Pre-arrayed siRNA Libraries	130
MISSION In Vivo Quality and iScale Oligos siRNA	130
N-TER Nanoparticle siRNA Transfection System	131
siRNA Controls (Positive and Negative)	131
MISSION shRNA Library	131
MISSION Lentiviral Controls	131
MISSION esiRNA	131
MISSION Human miRNA Mimics	132
LOCKED NUCLEIC ACID (LNA) PLATFORM (ROCHE [SANTARIS PHARMA])	132
TRIFECTA RNAI KIT (INTEGRATED DNA TECHNOLOGIES)	132
PSITEST SYSTEM (INVIVOGEN)	132

<b>TOPIC</b>	<b>PAGE NO.</b>
SELF-DELIVERABLE RNAI TECHNOLOGY (ADVIRNA)	133
RNAI TECHNOLOGIES (BIONEER CORP)	133
AccuTarget Libraries	133
AccuTarget Control siRNAs from Bioneer	133
AccuTarget Human miRNA Mimic and Inhibitor Library	133
Self-Assembled Micelle Inhibitory RNA (SAMiRNA)	134
POOLED LENTIVIRAL LIBRARIES (CELLECTA INC.)	134
NANOPARTICLE-DRUG CONJUGATES (NDCS) (CERULEAN PHARMA INC.)	134
ALLSTARS RNAI CONTROLS (QIAGEN N.V.)	134
RNAI TECHNOLOGIES (APPLIED BIOLOGICAL MATERIALS)	135
siRNA Adeno-Associated Virus (AAV)	135
iLenti RNAi Expression System	135
LIPID-ENABLED AND UNLOCKED NUCLEIC ACID MODIFIED RNA DELIVERY TECHNOLOGY (ARCTURUS THERAPEUTICS, INC.)	135
ELASTIN-LIKE POLYPEPTIDE (ELP) NANOPARTICLES (PEPTIMED INC.)	135
MICRORNA-BASED DIAGNOSTIC TESTS (ROSETTA GENOMICS)	136
The Rosetta Cancer Origin Test	136
The Rosetta Lung Cancer Test	136
The Rosetta Kidney Cancer Test	136
The Rosetta Mesothelioma Test	136
ATURNAI (SILENCE THERAPEUTICS)	136
DSIRNA-EX-CONJUGATES (DICERNA PHARMACEUTICALS INC.)	137
LODER (SILENSEED LTD.)	137
FACTORS AFFECTING THE RNA INTERFERENCE MARKET	137
CURRENT DRIVERS FOR THE RNA INTERFERENCE TECHNOLOGY MARKET	138
MERGER AND ACQUISITION ACTIVITIES	138
FUNDING FOR DEVELOPMENT OF RNA INTERFERENCE THERAPEUTICS AND TECHNOLOGIES	139
<i>TABLE 40 FUNDING FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015</i>	140
<i>TABLE 41 INVESTMENTS FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015</i>	142
CHAPTER 9 COMPANY PROFILES	145
ADVIRNA	145
ALNYLAM PHARMACEUTICALS, INC.	145
APEIRON BIOLOGICS AG	148
APPLIED BIOLOGICAL MATERIALS, INC.	148
ARBUSUS BIOPHARMA CORP. (PREVIOUSLY TEKMIIRA PHARMACEUTICALS CORP.)	148
ARCTURUS THERAPEUTICS, INC.	150
ARROWHEAD RESEARCH CORP.	151
ASCLETIS INC.	152
BENITEC BIOPHARMA LTD.	152
BIOGEN IDEC, INC.	153
BIOMICS BIOTECHNOLOGIES CO. LTD.	153
BIONEER CORP.	154
CELLECTA, INC.	154



<b>TOPIC</b>	<b>PAGE NO.</b>
CERULEAN PHARMA, INC.	155
DICERNA PHARMACEUTICALS, INC.	156
EXIQON A/S	157
F. HOFFMANN-LA ROCHE AG (ROCHE)	158
GENERAL ELECTRIC CO.	158
INTEGRATED DNA TECHNOLOGIES, INC.	160
INVIVOGEN	160
ISIS PHARMACEUTICALS, INC.	161
MARINA BIOTECH, INC.	161
MODERNA THERAPEUTICS	162
MONSANTO CO.	164
NITTO DENKO CORP.	164
PEPTIMED INC.	165
QIAGEN N.V.	166
QUARK PHARMACEUTICALS, INC.	166
REGULUS THERAPEUTICS	167
ROSETTA GENOMICS LTD.	168
RXI PHARMACEUTICALS CORP.	170
SANOFI	171
SIGMA-ALDRICH	172
SILENCE THERAPEUTICS PLC.	173
SILENSEED LTD.	174
SOLSTICE BIOLOGICS	174
SOMAGENICS, INC.	174
SUMITOMO DAINIPPON PHARMA CO. LTD.	175
SYNGENTA INTERNATIONAL AG	175
THE NATIONAL INSTITUTES OF HEALTH (NIH)	176
THE RNAI CONSORTIUM AT BROAD INSTITUTE OF MIT AND HARVARD	177
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	178
THERMO FISHER SCIENTIFIC, INC.	178
ZELTIA GROUP	179
CHAPTER 10 APPENDIX	182
GLOSSARY AND ABBREVIATIONS	182

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 EVOLUTION OF RNA	11
TABLE 2 MICRORNA (MIRNA) DATABASES	14
TABLE 3 SHORT/SMALL INTERFERING RNA (SIRNA) DATABASES	15
TABLE 4 PIWI-INTERACTING RNA (PIRNA) DATABASES	17
TABLE 5 STABILIZATION METHODS FOR LIPID BASED SIRNA DELIVERY SYSTEM	24
TABLE 6 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF RNAI THERAPEUTICS AND TECHNOLOGIES AS OF SEPTEMBER 2015	40
TABLE 7 GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, THROUGH 2020 (\$ MILLIONS)	50
TABLE 8 MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)	51
TABLE 9 MODIFICATIONS OF SIRNA	52
TABLE 10 RNAI VECTORS	53
TABLE 11 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, THROUGH 2020 (\$ MILLIONS)	56
TABLE 12 MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)	57
TABLE 13 DISEASE-SPECIFIC TARGET GENES/PROTEINS FOR RNAI THERAPEUTICS	59
TABLE 14 GLOBAL PHARMACEUTICAL MARKET, THROUGH 2020 (\$ BILLIONS)	60
TABLE 15 GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)	61
TABLE 16 TOP GLOBAL PHARMACEUTICAL COMPANIES BY SALES, 2014 (\$ MILLIONS)	62
TABLE 17 GLOBAL OUTLOOK OF THERAPEUTIC SPENDING BY DISEASE, THROUGH 2018 (\$ BILLION/%)	69
TABLE 18 NUMBER OF PUBLICATIONS ASSOCIATED WITH MIRNA AND DISEASES, OCTOBER 2015	73
TABLE 19 MIRNA IN VARIOUS CANCER TYPES	75
TABLE 20 MIRNA AND TARGET GENE PAIRS IN VARIOUS CANCER TYPES	77
TABLE 21 BIOMARKERS IN VARIOUS CANCER TYPES	80
TABLE 22 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, THROUGH 2020 (\$ MILLIONS)	86
TABLE 23 GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, THROUGH 2020 (\$ MILLIONS)	87
TABLE 24 SAFETY ISSUES WITH RNAI CROP IMPROVEMENT	89
TABLE 25 PLANT IMPROVEMENT AREAS THROUGH RNAI TECHNOLOGIES	92
TABLE 26 REGIONS, GENES AND APPLICATION OF RNAI-TARGETING ORGANISMS FOR IMPROVEMENT OF CROPS	92
TABLE 27 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, THROUGH 2020 (\$ MILLIONS)	97
TABLE 28 GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)	97
TABLE 29 GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	99
TABLE 30 GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)	100
TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF RNAI RESEARCH TOOLS AND REAGENTS, 2014	102
TABLE 32 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)	108
TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF RNAI DIAGNOSTICS, 2014	109

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 34 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)	110
TABLE 35 TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015	113
TABLE 36 NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015	114
TABLE 37 PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)	115
TABLE 38 NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COMPANY, 2013-AUGUST 2015	117
TABLE 39 NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST 2015	120
TABLE 40 FUNDING FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015	140
TABLE 41 INVESTMENTS FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015	142

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020 (\$ MILLIONS)	8
FIGURE 1 GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, 2013-2020 (\$ MILLIONS)	50
FIGURE 2 MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)	51
FIGURE 3 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, 2013-2020 (\$ MILLIONS)	56
FIGURE 4 MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)	57
FIGURE 5 GLOBAL PHARMACEUTICAL SALES MARKET, 2013-2020 (\$ BILLIONS)	60
FIGURE 6 GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)	61
FIGURE 7 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, 2013-2020 (\$ MILLIONS)	86
FIGURE 8 GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, 2013-2020 (\$ MILLIONS)	87
FIGURE 9 GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2013-2020 (\$ MILLIONS)	97
FIGURE 10 GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)	98
FIGURE 11 GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, 2013-2020 (\$ MILLIONS)	99
FIGURE 12 GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)	100
FIGURE 13 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)	109
FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)	110
FIGURE 15 TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015	113
FIGURE 16 PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)	115
FIGURE 17 NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST, 2015	120